Ryan Cross

Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma

Rebecca C Abbott, Melinda Iliopoulos, Katherine A Watson, Valeria Arcucci, Margareta Go, Hannah E Hughes-Parry, Pete Smith, Melissa J Call, Ryan S Cross, Misty R Jenkins

Journal article  |  2023  |  CLINICAL & TRANSLATIONAL IMMUNOLOGY

OBJECTIVES: Glioblastoma is a highly aggressive and fatal brain malignancy, and effective targeted therapies are required. The com..

MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms

Lap Hing Chi, Ryan SN Cross, Richard P Redvers, Melissa Davis, Soroor Hediyeh-zadeh, Suresh Mathivanan, Monisha Samuel, Erin C Lucas, Kellie Mouchemore, Philip A Gregory, Cameron N Johnstone, Robin L Anderson

Journal article  |  2022  |  ONCOGENESIS

MiR-21 was identified as a gene whose expression correlated with the extent of metastasis of murine mammary tumours. Since miR-21 ..

De novo-designed transmembrane domains tune engineered receptor functions

Assaf Elazar, Nicholas J Chandler, Ashleigh S Davey, Jonathan Y Weinstein, Julie Nguyen, Raphael Trenker, Ryan S Cross, Misty R Jenkins, Melissa J Call, Matthew E Call, Sarel J Fleishman

Journal article  |  2022  |  ELIFE

De novo-designed receptor transmembrane domains (TMDs) present opportunities for precise control of cellular receptor functions. W..

BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells

Diane Moujalled, Adam G Southon, Eiman Saleh, Kerstin Brinkmann, Francine Ke, Melinda Iliopoulos, Ryan S Cross, Misty R Jenkins, Duong Nhu, Zilu Wang, Melissa X Shi, Ruth M Kluck, Guillaume Lessene, Stephanie Grabow, Ashley Bush, Andreas Strasser

Journal article  |  2022  |  CELL DEATH AND DIFFERENTIATION

Glioblastoma multiforme (GBM) is the most common and aggressive form of brain cancer, with treatment options often constrained due..

A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell Forms a T Cell-like Immune Synapse

Stacie Shiqi Wang, Kylie Luong, Fiona Margaret Gracey, Shereen Jabar, Brad McColl, Ryan Stanley Cross, Misty Rayna Jenkins

Journal article  |  2021  |  BIOMEDICINES

Chimeric Antigen Receptor (CAR) T cell therapy is a promising form of adoptive cell therapy that re-engineers patient-derived T ce..

Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma

Rebecca C Abbott, Daniel J Verdon, Fiona M Gracey, Hannah E Hughes-Parry, Melinda Iliopoulos, Katherine A Watson, Matthias Mulazzani, Kylie Luong, Colleen D'Arcy, Lucy C Sullivan, Ben R Kiefel, Ryan S Cross, Misty R Jenkins

Journal article  |  2021  |  CLINICAL & TRANSLATIONAL IMMUNOLOGY

OBJECTIVES: The increasing success of Chimeric Antigen Receptor (CAR) T cell therapy in haematological malignancies is reinvigorat..

Erratum: Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.

Rebecca C Abbott, Daniel J Verdon, Fiona M Gracey, Hannah E Hughes-Parry, Melinda Iliopoulos, Katherine A Watson, Matthias Mulazzani, Kylie Luong, Colleen D'Arcy, Lucy C Sullivan, Ben R Kiefel, Ryan S Cross, Misty R Jenkins

Journal article  |  2021  |  Clin Transl Immunology

[This corrects the article DOI: 10.1002/cti2.1283.].

Nurturing evidence‐based practice change in the Australian healthcare system

Amanda J Cross, Ryan S Cross

Journal article  |  2020  |  Journal of Pharmacy Practice and Research

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies

Rebecca C Abbott, Ryan S Cross, Misty R Jenkins

Journal article  |  2020  |  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Oncology immunotherapy has been a significant advancement in cancer treatment and involves harnessing and redirecting a patient's ..

The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells

Hannah E Hughes-Parry, Ryan S Cross, Misty R Jenkins

Journal article  |  2020  |  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The clinical success of chimeric antigen receptor (CAR) T cell immunotherapy in the treatment of haematological cancers has encour..